10-Q: Range Impact Inc. Reports Q2 2024 Results: Revenue Declines Amid Subcontractor Issues, Strategic Shift Continues

Range Impact Inc. reported a decrease in revenue and a net loss for the second quarter of 2024, primarily due to a subcontractor's failure to perform and increased operating expenses, while continuing its strategic shift towards impact investing.

Summary

• Range Impact Inc. reported a revenue of $2,349,738 for the three months ended June 30, 2024, a decrease from $3,998,267 in the same period of 2023.
• The company experienced a gross loss of $148,929 for the quarter, compared to a gross profit of $845,101 in the prior year.
• Net loss for the quarter was $1,225,681, a significant downturn from a net income of $36,762 in the second quarter of 2023.
• For the six months ended June 30, 2024, revenue was $6,259,631, down from $7,013,154 in the same period of 2023.
• The company's gross loss for the first half of 2024 was $130,075, compared to a gross profit of $1,494,103 in the first half of 2023.
• The net loss for the first six months of 2024 was $2,439,521, a substantial decrease from a net loss of $190,098 in the first half of 2023.
• The decline in revenue was primarily attributed to a subcontractor's failure to perform in the Range Reclaim and Range Minerals segments.
• Operating expenses increased to $854,977 for the quarter and $1,930,518 for the six months, due to additional employees and consultants.
• Research and development costs also increased to $157,278 for the quarter and $288,918 for the six months, due to the allocation of a corporate executive's salary to the Graphium Biosciences segment.
• The company had a negative working capital of $403,621 as of June 30, 2024, compared to a positive working capital of $753,756 as of December 31, 2023.
• The company issued 3,703,704 shares of common stock for $1,000,000 during the quarter.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with significant revenue decline, a shift to a gross loss, and a substantial net loss. The negative working capital and material weakness in internal controls further contribute to a negative sentiment. While the company has some positive initiatives, the current financial performance and risks outweigh the positives.

Positives

• Range Security revenue increased due to a new security services contract.
• The company is actively pursuing innovative solutions in environmental services, biochar, and drug development.
• The company has a strategic focus on impact investing in economically disadvantaged regions.
• The company is developing a proprietary, biochar-based passive treatment system for mine site discharges.
• The company is exploring the use of former mine land for renewable energy facilities and other non-fossil fuel uses.
• The company has a portfolio of glycosylated cannabinoid prodrugs with potential therapeutic benefits.
• The company has received Orphan Drug Designation for its glycosylated cannabinoid VBX-100 for the treatment of pediatric ulcerative colitis.

Negatives

• The company experienced a significant decrease in revenue and profitability in the Range Reclaim and Range Minerals segments.
• A subcontractor's failure to perform negatively impacted revenue and profitability.
• The company's net loss increased substantially compared to the same period last year.
• The company's working capital turned negative, indicating potential liquidity challenges.
• The company is heavily reliant on two major customers for revenue.
• The company has a material weakness in internal control over financial reporting related to expense recording and accruals.
• The company is subject to extensive regulation by the FDA and DEA due to its drug development activities.

Risks

• The company's ability to obtain additional financing is uncertain.
• The company's ability to continue operating as a going concern is dependent on securing additional funding.
• The company faces competition from larger and better-capitalized businesses.
• The company's research and development activities may not yield positive results.
• The company's ability to bring its intended products to market is not guaranteed.
• The company is subject to fluctuations in the availability and costs of raw materials.
• The company's reliance on a few major customers poses a concentration risk.
• The company's internal control over financial reporting has a material weakness.
• The company's drug development activities are subject to regulatory risks and may not be successful.

Future Outlook

The company expects its operating businesses to generate operating losses over the next 12 months, but anticipates having sufficient funds to operate based on current cash balance and the collection of outstanding accounts receivable. The company will explore financing options if additional capital is needed.

Management Comments

• Range takes an opportunistic approach to impact investing by leveraging its competitive advantages and looking at solving old problems in new ways.
• Range seeks to thoughtfully allocate its capital into strategic opportunities that are expected to make a positive impact on the people-planet ecosystem and generate strong investment returns for its shareholders.
• We strive to instill a corporate culture of honesty, integrity and respect while advancing our mission of doing well by doing good.
• Our impact investing strategy provides an opportunity for our dedicated team to address pressing environmental, social and economic challenges, such as air and water pollution, educational inequality and economic disparity, and climate change, through the development of technology-based solutions.
• We believe that doing well and doing good are not mutually exclusive, and that an impact investing strategy can balance the environmental, social and economic needs of people and the planet while also generating attractive risk-adjusted financial returns for shareholders.

Industry Context

The company operates in the growing impact investing market, focusing on environmental and social solutions in the Appalachian region. The decline in coal mining has created a need for land reclamation and repurposing, which Range Impact aims to address. The company's biochar and drug development initiatives also align with broader trends in sustainable agriculture, water treatment, and pharmaceutical innovation.

Comparison to Industry Standards

• The company's revenue decline is concerning compared to industry averages, which have shown growth in the environmental services sector.
• The shift from a gross profit to a gross loss is a significant deviation from industry norms, indicating potential issues with cost management or pricing strategies.
• The negative working capital position is a red flag, as most companies in the sector maintain a positive working capital to ensure operational stability.
• The company's reliance on two major customers is a higher concentration risk than what is typically seen in the industry, where companies strive for a diversified customer base.
• The material weakness in internal control over financial reporting is a serious concern, as it indicates a lack of proper oversight and could lead to further financial misstatements.
• The company's focus on impact investing and its unique approach to land reclamation and biochar development are differentiating factors, but their financial performance needs to improve to be competitive.
• Compared to established environmental services companies like Tetra Tech or AECOM, Range Impact is still in its early stages and needs to demonstrate consistent revenue growth and profitability.
• In the pharmaceutical sector, companies like AbbVie or Johnson & Johnson have significantly more resources and established pipelines, making it challenging for Range Impact to compete in the drug development space.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material pending legal proceedings that would have a material adverse effect on its financial position or results of operations.

Stakeholder Impact

• Shareholders are negatively impacted by the significant decrease in revenue and profitability, as well as the negative working capital.
• Employees may be impacted by potential cost-cutting measures or restructuring due to the company's financial challenges.
• Customers may be impacted by potential delays or disruptions in services due to the subcontractor issues.
• Suppliers may be impacted by potential delays in payments due to the company's financial challenges.
• Creditors may be concerned about the company's ability to repay its debts due to the negative working capital and net losses.

Next Steps

• The company plans to expand its market share with existing coal mining customers and reclamation bond insurers.
• The company will seek to add additional people, equipment and technologies to support its growth goals.
• The company is evaluating the purchase of a large continuous-process pyrolysis oven to increase the scale of its biochar production.
• The company plans to expand its security service business to additional mine sites.
• The company is actively reviewing several mine sites throughout Appalachia to acquire, reclaim and repurpose.
• The company is working with a third-party contract research organization to advance its leading drug candidate, VBX-100, through Phase II clinical trials by the end of 2027.

Key Dates

Keywords

impact investing, land reclamation, water restoration, biochar, cannabinoid prodrugs, mine reclamation, environmental services, drug development, Appalachia, renewable energy